



Toxicological Profile for Cobalt

Draft for Public Comment

January 2023



U.S. Department of Health and Human Services
Agency for Toxic Substances and Disease Registry

DISCLAIMER

Use of trade names is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry, the Public Health Service, or the U.S. Department of Health and Human Services.

This information is distributed solely for the purpose of pre dissemination public comment under applicable information quality guidelines. It has not been formally disseminated by the Agency for Toxic Substances and Disease Registry. It does not represent and should not be construed to represent any agency determination or policy.

FOREWORD

This toxicological profile is prepared in accordance with guidelines developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for these toxic substances described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a relevance to public health discussion which would allow a public health professional to make a real-time determination of whether the presence of a particular substance in the environment poses a potential threat to human health. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to the protection of public health are identified by ATSDR and EPA.

Each profile includes the following:

- (A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a toxic substance to ascertain the levels of significant human exposure for the substance and the associated acute, intermediate, and chronic health effects;
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine the levels of exposure that present a significant risk to human health due to acute, intermediate, and chronic duration exposures; and
- (C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public. ATSDR plans to revise these documents in response to public comments and as additional data become available. Therefore, we encourage comments that will make the toxicological profile series of the greatest use.

Electronic comments may be submitted via: www.regulations.gov. Follow the on-line instructions for submitting comments.

Written comments may also be sent to: Agency for Toxic Substances and Disease Registry
Office of Innovation and Analytics
Toxicology Section
1600 Clifton Road, N.E.
Mail Stop S102-1
Atlanta, Georgia 30329-4027

The toxicological profiles are developed under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund). CERCLA section 104(i)(1) directs the Administrator of ATSDR to "...effectuate and implement the health related authorities" of the statute. This includes the preparation of toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List (NPL) and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list. In addition, ATSDR has the authority to prepare toxicological profiles for substances not found at sites on the NPL, in an effort to "...establish and maintain inventory of literature, research, and studies on the health effects of toxic substances" under CERCLA Section 104(i)(1)(B), to respond to requests for consultation under section 104(i)(4), and as otherwise necessary to support the site-specific response actions conducted by ATSDR.

This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staffs of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and is being made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.



Patrick N. Breyse, Ph.D., CIH
Administrator, National Center for Environmental
Health and
Agency for Toxic Substances and Disease Registry
Centers for Disease Control and Prevention



Christopher M. Reh, PhD
Associate Director
Agency for Toxic Substances and Disease
Registry
Centers for Disease Control and Prevention

VERSION HISTORY

Date	Description
January 2023	Draft for public comment released
April 2004	Final toxicological profile released
July 1992	Final toxicological profile released

CONTRIBUTORS & REVIEWERS

CHEMICAL MANAGER TEAM

Sam Keith, MS, CHP (Lead)
Obaid Faroon D.V.M., Ph.D.

Rekha C. Balachandran, M.S, Ph.D.
Adriana Antezana, M.P.H.
Hannah Derrick, B.S.
Kerry Diskin, Ph.D.
Andrea Chiger, M.P.H.
Meghan Lynch, Ph.D.

ATSDR, Office of Innovation and Analytics,
Toxicology Section, Atlanta, GA

Abt Associates, Cambridge, MA

Bruce Fowler, Ph.D.
Toxicology and Risk Assessment
Consulting Services, Rockville, MD
(under subcontract to Abt Associates)

REVIEWERS

Interagency Minimal Risk Level Workgroup:

Includes ATSDR; National Center for Environmental Health (NCEH); National Institute for Occupational Safety and Health (NIOSH); U.S. Environmental Protection Agency (EPA); National Toxicology Program (NTP).

Additional reviews for science and/or policy:

ATSDR, Office of Community Health and Hazard Assessment; ATSDR, Office of Capacity Development and Applied Prevention Science; ATSDR, Office of Science; NCEH, Division of Laboratory Science; NCEH, Division of Environmental Health Science and Practice; EPA.

PEER REVIEWERS

1. David Dorman, DVM, PhD, DABVT, DABT, Professor of Toxicology, Department of Molecular Biomedical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina
2. Katherine Zychowski, PhD, Assistant Professor, College of Pharmacy, The University of New Mexico, Albuquerque, NM, USA
3. Ruth Danzeisen, PhD, DABT, Advisor Toxicology, Albemarle, Germany-NI Langelsheim (LHM)

These experts collectively have knowledge of toxicology, chemistry, and/or health effects. All reviewers were selected in conformity with Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

ATSDR scientists review peer reviewers' comments and determine whether changes will be made to the profile based on comments. The peer reviewers' comments and responses to these comments are part of the administrative record for this compound.

The listing of peer reviewers should not be understood to imply their approval of the profile's final content. The responsibility for the content of this profile lies with ATSDR.

CONTENTS

DISCLAIMER	ii
FOREWORD	iii
VERSION HISTORY	v
CONTRIBUTORS & REVIEWERS	vi
CONTENTS.....	viii
LIST OF FIGURES	x
LIST OF TABLES	xi
CHAPTER 1. RELEVANCE TO PUBLIC HEALTH	1
1.1. OVERVIEW AND U.S. EXPOSURES.....	1
1.2. SUMMARY OF HEALTH EFFECTS	2
1.3. MINIMAL RISK LEVELS (MRLs).....	7
CHAPTER 2. HEALTH EFFECTS.....	12
2.1. INTRODUCTION	12
2.2. DEATH.....	90
2.3. BODY WEIGHT	91
2.4. RESPIRATORY	93
2.5. CARDIOVASCULAR.....	97
2.6. GASTROINTESTINAL	100
2.7. HEMATOLOGICAL.....	101
2.8. MUSCULOSKELETAL.....	104
2.9. HEPATIC.....	105
2.10. RENAL	108
2.11. DERMAL.....	110
2.12. OCULAR.....	111
2.13. ENDOCRINE	111
2.14. IMMUNOLOGICAL.....	113
2.15. NEUROLOGICAL	115
2.16. REPRODUCTIVE	118
2.17. DEVELOPMENTAL.....	120
2.18. OTHER NONCANCER	121
2.19. CANCER	122
2.20. GENOTOXICITY.....	124
2.21. MECHANISM OF ACTION.....	128
2.22. COBALT NANOPARTICLES.....	130
CHAPTER 3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS	132
3.1. TOXICOKINETICS	132
3.1.1. Absorption.....	132
3.1.2. Distribution	139
3.1.3. Metabolism	143
3.1.4. Excretion.....	143
3.1.5. Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models.....	151
3.1.6. Animal-to-Human Extrapolations.....	156
3.2. CHILDREN AND OTHER POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE	156
3.3. BIOMARKERS OF EXPOSURE AND EFFECT.....	159
3.3.1. Biomarkers of Exposure.....	159
3.3.2. Biomarkers of Effect.....	160
3.4. INTERACTIONS WITH OTHER CHEMICALS.....	161
CHAPTER 4. CHEMICAL AND PHYSICAL INFORMATION	163

4.1. CHEMICAL IDENTITY	163
4.2. PHYSICAL AND CHEMICAL PROPERTIES	164
CHAPTER 5. POTENTIAL FOR HUMAN EXPOSURE	168
5.1. OVERVIEW	168
5.2. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL	171
5.2.1. Production	171
5.2.2. Import/Export	174
5.2.3. Use	174
5.2.4. Disposal	175
5.3. RELEASES TO THE ENVIRONMENT	175
5.3.1. Air	180
5.3.2. Water	181
5.3.3. Soil	182
5.4. ENVIRONMENTAL FATE	182
5.4.1. Transport and Partitioning	182
5.4.2. Transformation and Degradation	186
5.5. LEVELS IN THE ENVIRONMENT	189
5.5.1. Air	190
5.5.2. Water	191
5.5.3. Sediment and Soil	192
5.5.4. Other Media	193
5.6. GENERAL POPULATION EXPOSURE	195
5.7. POPULATIONS WITH POTENTIALLY HIGH EXPOSURES	205
CHAPTER 6. ADEQUACY OF THE DATABASE	212
6.1. EXISTING INFORMATION ON HEALTH EFFECTS	212
6.2. IDENTIFICATION OF DATA NEEDS	213
6.3. ONGOING STUDIES	219
CHAPTER 7. REGULATIONS AND GUIDELINES	220
CHAPTER 8. REFERENCES	224
APPENDIX A. ATSDR MINIMAL RISK LEVELS AND WORKSHEETS	A-1
APPENDIX B. LITERATURE SEARCH FRAMEWORK FOR COBALT	B-1
APPENDIX C. FRAMEWORK FOR ATSDR'S SYSTEMATIC REVIEW OF HEALTH EFFECTS DATA FOR COBALT	C-1
APPENDIX D. USER'S GUIDE	D-1
APPENDIX E. QUICK REFERENCE FOR HEALTH CARE PROVIDERS	E-1
APPENDIX F. GLOSSARY	F-1
APPENDIX G. ACRONYMS, ABBREVIATIONS, AND SYMBOLS	G-1

LIST OF FIGURES

Figure 1-1. Health Effects Found in Humans and Animals Following Inhalation Exposure to Cobalt.....	6
Figure 1-2. Health Effects Found in Humans and Animals Following Oral Exposure to Cobalt.....	7
Figure 1-3. Summary of Sensitive Targets of Cobalt–Inhalation	9
Figure 1-4. Summary of Sensitive Targets of Cobalt–Oral	10
Figure 2-1. Overview of the Number of Studies Examining Cobalt Health Effects.....	14
Figure 2-2. Levels of Significant Exposure to Cobalt–Inhalation	37
Figure 2-3. Levels of Significant Exposure to Cobalt–Oral	73
Figure 2-4. Mechanistic Events Associated with Cobalt Toxicity and Carcinogenicity	130
Figure 3-1. Modeling Indicates Particle Size is Crucial for Absorption of Cobalt from Lungs to Blood after Inhalation Exposure: 0.8 μm porous Co_3O_4	134
Figure 3-2. Modeling Indicates Particle Size is Crucial for Absorption of Cobalt from Lungs to Blood after Inhalation Exposure: 1.7 μm porous Co_3O_4	135
Figure 3-3. Modeling Indicates Particle Size is Crucial for Absorption of Cobalt from Lungs to Blood after Inhalation Exposure: 0.9 μm solid Co_3O_4	135
Figure 3-4. Cobalt Levels in rat tissue after 90-day oral exposure to 30 mg/kg bw/day CoCl_2 (7.44 mg Co/kg bw/day) compared to controls (means \pm SD).....	142
Figure 3-5. Alimentary Tract Model and Transfer Coefficients (ICRP 2016).....	153
Figure 3-6. Detailed Systemic Model	154
Figure 3-7. Updated Model Inhalation.....	155
Figure 5-1. Number of NPL Sites with Cobalt Contamination.....	168
Figure 6-1. Summary of Existing Health Effects Studies on Cobalt by Route and Endpoint.....	213

LIST OF TABLES

Table 1-1. Minimal Risk Levels (MRLs) for Cobalt	11
Table 2-1. Levels of Significant Exposure to Cobalt – Inhalation.....	17
Table 2-2. Levels of Significant Exposure to Cobalt – Oral.....	49
Table 2-3. Levels of Significant Exposure to Cobalt – Dermal.....	82
Table 2-4. Occupational Exposures to Cobalt and Health Outcome Associations	84
Table 2-5. Environmental Exposure to Cobalt and Health Outcome Associations in Human Studies.....	88
Table 2-6. Oral Exposure to Cobalt and Health Outcome Associations in Human Studies	89
Table 2-7. Genotoxicity of Cobalt In Vivo	126
Table 2-8. Genotoxicity of Cobalt In Vitro.....	127
Table 3-1. Peak Translocation and Average Mechanical Clearance Rates (%) After Inhalation of Cobalt Oxide for 180 days.....	145
Table 3-2. Initial (Day 3) Lung Deposits of Cobalt Oxide and Summary of Lung Retention.....	145
Table 3-3. Retention of Cobalt (CoCl ₂) in Whole Blood and Serum in Humans after Oral Dosing	147
Table 3-4. Summary of Retention and Excretion After Intra-gastric Administration of Cobalt Oxide (Co ₃ O ₄) Particles (Mean Percentage of Recovered Activity at 7 Days Post Administration)	148
Table 3-5. Pharmacokinetic Parameters for Orally Administered Cobalt in Rats	148
Table 3-6. Urinary Cobalt Levels in Rats Following Oral Exposure to Cobalt	149
Table 3-7. Cobalt Levels in Rat Feces Following Oral Exposure to Cobalt	149
Table 3-8. Summary of Retention and Excretion of Cobalt Following Injection of Cobalt Nitrate Co(NO ₃) ₂ Solution (Mean Percent Recovery)	151
Table 4-1. Chemical Identity of Cobalt and Selected Cobalt Compounds	163
Table 4-2. Physical and Chemical Properties of Cobalt and Selected Cobalt Compounds	165
Table 5-1. Facilities that Produce, Process, or Use Cobalt or Cobalt Compounds.....	172
Table 5-2. Releases to the Environment from Facilities that Produce, Process, or Use Cobalt.....	176
Table 5-3. Releases to the Environment from Facilities that Produce, Process, or Use Cobalt Compounds	178
Table 5-4. Lowest Limit of Detection for Cobalt Based on Standards	189
Table 5-5. Cobalt Levels in Water, Soil, and Air of National Priorities List (NPL) Sites.....	190
Table 5-6. Percentile Distribution of Annual Mean Cobalt (TSP) Concentrations (µg/m ³) Measured in Ambient Air Locations Across the United States	190
Table 5-7. Geometric Mean and Selected Percentiles of Urinary Cobalt (in µg/L) for the U.S. Population from the National Health and Nutrition Examination Survey (NHANES) (CDC 2022).....	199

Table 5-8. Geometric Mean and Selected Percentiles of Blood Cobalt (in $\mu\text{g/L}$) for the U.S. Population from the National Health and Nutrition Examination Survey (NHANES) (CDC 2022).....	201
Table 5-9. Geometric Mean and Selected Percentiles of Urinary Cobalt (creatinine corrected) (in $\mu\text{g/g}$ of creatinine) for the U.S. Population from the National Health and Nutrition Examination Survey (NHANES) (CDC 2022).....	202
Table 7-1. Regulations and Guidelines Applicable to Cobalt.....	220